Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 13.
doi: 10.1111/jdv.70009. Online ahead of print.

Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

Filip Rob  1 , Spyridon Gkalpakiotis  2 , Martina Kojanová  3 , Yvetta Vantuchová  4 , Jarmila Čelakovská  5 , Jiří Horažďovský  6 , Monika Baláž  7   8 , Miroslav Nečas  9 , David Stuchlík  10 , Petra Cetkovská  11 , Kateřina Hrazdírová  12 , Alena Machovcová  13 , Blanka Pinková  14 , Jana Třešňák Hercogová  15
Affiliations

Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

Filip Rob et al. J Eur Acad Dermatol Venereol. .
No abstract available

Keywords: JAK inhibitors; atopic dermatitis; dupilumab; effectiveness; lebrikizumab; safety.

PubMed Disclaimer

References

REFERENCES

    1. Silverberg JI, Guttman‐Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate‐to‐severe atopic dermatitis. N Engl J Med. 2023;388:1080–1091.
    1. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate‐to‐severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159:182–191.
    1. Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate‐to‐severe atopic dermatitis: a 52‐week, open‐label, phase 3 study. Dermatol Ther (Heidelb). 2023;13:1517–1534.
    1. Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. Real‐world effectiveness and safety of lebrikizumab for moderate‐to‐severe atopic dermatitis: a 16‐week study in Japan. Dermatitis. 2025. https://doi.org/10.1089/derm.2025.0004. Online ahead of print.
    1. Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. 24‐week real‐world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: an analysis stratified by prior systemic therapy. Dermatitis. 2025. https://doi.org/10.1089/derm.2025.0045. Online ahead of print.

LinkOut - more resources